Study Findings from Sub‑Saharan Africa
A multi‑country analysis published in BMC Public Health examined HIV drug‑resistance data gathered through the Population‑based HIV Impact Assessment (PHIA) surveys conducted between 2015 and 2019. The researchers pooled results from nine sub‑Saharan nations and found that more than one‑third of adults receiving antiretroviral therapy (ART) harbored at least one resistance‑associated mutation. The majority of these mutations were linked to drugs used in first‑line regimens, such as tenofovir, lamivudine and efavirenz, and were detected among individuals with unsuppressed viral loads (≥1,000 copies/mL). The study concluded that acquired resistance—arising after treatment initiation—was the dominant driver, rather than transmitted (pre‑treatment) resistance.
Why the Findings Matter
Drug‑resistant HIV compromises the efficacy of standard ART, leading to higher rates of viral rebound, increased risk of disease progression, and greater transmission potential. The World Health Organization (WHO) estimates that, globally, drug resistance threatens the sustainability of treatment programs and could reverse gains made toward the 2030 AIDS‑free targets according to its fact sheet on HIV drug resistance. In regions where ART coverage has expanded rapidly, surveillance data like those from PHIA are essential for guiding timely regimen switches and bolstering adherence support.
Expert Commentary
Dr. Anna Meyer, an epidemiologist with the WHO Global HIV Programme, noted that “the high prevalence of acquired resistance underscores gaps in routine viral‑load monitoring and timely treatment adjustments.” She referenced WHO’s recommendation that countries implement regular surveillance of acquired resistance using either nationally representative laboratory‑based or clinic‑based surveys as outlined in its surveillance guidance. Dr. Meyer added that strengthening adherence counseling and ensuring uninterrupted drug supply are immediate priorities to reduce the emergence of resistance.
Public‑Health Implications
The study’s results align with WHO’s broader concerns about rising resistance to integrase inhibitors such as dolutegravir, which have become the preferred first‑line drugs in many African settings. Recent WHO briefings have reported dolutegravir resistance rates ranging from 3.9 % to 8.6 % among patients with detectable viral loads, with higher percentages in those with extensive treatment histories as highlighted in a 2024 WHO brief. These figures, combined with the PHIA findings, suggest that without intensified monitoring, the effectiveness of dolutegravir‑based regimens could be jeopardized.
Country programs are urged to reinforce three pillars: (1) universal access to timely viral‑load testing, (2) robust adherence interventions—including community‑based peer support—and (3) rapid transition to second‑line therapies when suppression is not achieved. In practice, this may involve deploying point‑of‑care viral‑load platforms, training health‑care workers on resistance interpretation, and expanding differentiated service delivery models that reduce missed appointments.
Next Steps in Research and Policy
Future investigations should focus on longitudinal cohorts to track the evolution of resistance mutations after regimen switches, as well as the impact of long‑acting pre‑exposure prophylaxis (PrEP) on resistance patterns. The WHO’s Integrated Drug Resistance Action Framework, launched for the 2026–2030 period, calls for coordinated surveillance across HIV, hepatitis and sexually transmitted infections, emphasizing data sharing and capacity building in its recent strategy document. Implementing these recommendations will help safeguard the durability of ART programmes and protect public health gains across sub‑Saharan Africa.
For clinicians and patients alike, the key takeaway is that staying adherent to ART and accessing regular viral‑load testing remain the most effective defenses against drug resistance. Health ministries, partners and communities must collaborate to close the gaps identified by the PHIA analysis, ensuring that the promise of lifelong viral suppression can be realized for all people living with HIV.
Read more on Globally Pulse Health.
